Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 7/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 4/20 | 0.34 |
| ▸ | TYK2 | P29597 | 4/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469633 | 0.85 | SLC16A3 (0.37) | SLC16A3AAK1FFAR1 | |
| SCHEMBL17469628 | 0.79 | ASIC3 (0.38) | SLC16A3AAK1FFAR1 | |
| SCHEMBL18999199 | 0.76 | TMPRSS2 (0.33) | SLC16A3 | |
| SCHEMBL17469634 | 0.73 | GRM5 (0.36) | SLC16A3 | |
| SCHEMBL17469730 | 0.72 | TMPRSS2 (0.48) | SLC16A3 | |
| SCHEMBL18999200 | 0.72 | ASIC3 (0.38) | SLC16A3 | |
| SCHEMBL21152726 | 0.70 | ASIC3 (0.39) | SLC16A3 | |
| SCHEMBL17469627 | 0.67 | CHRM2 (0.34) | SLC16A3 | |
| SCHEMBL17469632 | 0.65 | SLC16A3 (0.40) | SLC16A3 | |
| SCHEMBL28353255 | 0.64 | FFAR1 (0.56) | AAK1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | SLC16A3 4161/4885AAK1 4258/4885JAK1 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.